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Abstract
Background: Given the side effects associated with intravenous injections of interferon, an interferon-free regimen
for the treatment of HCV infections is highly desirable. Recently published clinical studies show that interferon-free
combination therapies containing ribavirin are efficacious, suggesting that an interferon-free therapy could be
adopted in the near future. Therefore, understanding HCV resistance to ribavirin could be of major importance. In
an approach to understand the effect of ribavirin on HCV replication and HCV resistance, we have selected a
ribavirin resistant mutant of HCV in vitro.
Methods: We serially passed the J6/JFH1 strain of HCV in Huh7D cells (a Huh7 cell derivative more permissive to
HCV replication) in the presence of different concentrations of ribavirin. Virus replication was assessed by detection
of HCV antigens by immunfluorscence of infected cells and titration of recovered virus present in the supernatant.
cDNAs from virus RNA grown in 0 or 250 uM concentrations of ribavirin were synthesized by RT-PCR, and
sequenced.
Results: A concentration of 125 uM of ribavirin did not have a dramatic effect on HCV replication, while 500 uM of
ribavirin lead to viral extinction. Concentrations of 250 uM of ribavirin dramatically reduced virus replication which
was sustained over six passages. At passage seven viral resurgence began and over two passages the level of virus
reached that of the wild type virus grown without ribavirin. Virus recovered from these cultures were more
resistant to 250 uM ribavirin than wild type virus, and showed no difference in replication relative to wild type
virus when grown in the absence of ribavirin. The ribavirin resistant virus accumulated multiple synonymous and
non-synonymous mutations that are presently being analyzed for their relationship to ribavirin resistance.
Conclusions: It is possible to select a ribavirin resistant mutant of HCV that can replicate to levels similar to wild
type virus grown without ribavirin. Analysis of the mutations responsible for the ribavirin resistance may aid in
understanding the mechanism of action of ribavirin.
Background
While mono-therapy regimens of ribavirin have minimal
effect on patients with chronic HCV infections, ribavirin
clearly has a synergistic effect when combined with
interferon. Therefore, understanding how ribavirin sup-
presses HCV replication and how HCV could escape the
effect of ribavirin could be of major importance. Pro-
posed mechanisms of action of ribavirin against HCV
include a direct effect against the HCV RNA dependent
RNA polymerase (NS5b); induction of misincorporation
of nucleotides leading to lethal mutagenesis; depletion
of intracellular guanosine triphosphate pools; alteration
in the cytokine balance from a Th2 profile to a Th1
profile; and up-regulation of genes involved in interferon
signaling [1,2]. Clinical studies showed that the efficacy
of a interferon-free combination therapy involving a
protease and a polymerase inhibitor can be strongly
enhanced by adding ribavirin, suggesting a direct anti-
viral action of ribavirin in vivo [3,4]. However, the
mechanism of action of ribavirin is not completely
understood. Availability of an HCV ribavirin resistant
mutant could be useful to study the anti-HCV mechan-
ism of action of ribavirin and HCV resistance. In addi-
tion, a ribavirin resistant HCV mutant could be used to
study the cross-resistance of HCV to ribavirin and other
nucleoside analogs. To date, the reported HCV ribavirin
resistant mutants were based on HCV replicons and
transient assays [5-7]. Here we report the selection of a
ribavirin resistant HCV mutant that can replicate in
vitro to high levels in the presence of high concentra-
tions of ribavirin. The ribavirin resistant virus
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the HCV genome that are presently being analyzed.
Results
Selection of HCV resistant to ribavirin
In an approach to select a robust HCV resistant mutant
we passed the J6/JFH1 strain of HCV[8] in the presence
of different concentrations of ribavirin. Preliminary
experiments showed that Huh7D cells could grow to
confluence in concentrations of ribavirin up to 500 μM
(although at a slower rate than in absence of ribavirin)
and concentrations of 250 μM ribavirin and higher
affected the growth of HCV in persistently infected cells
(not shown). In addition, it has been reported that
Huh7 cells can acquire resistance to ribavirin by restrict-
ing ribavirin uptake[6,9]. Therefore, in order to avoid
the selection of ribavirin-resistant-cells that would allow
the virus to grow in ribavirin containing medium (with-
out being an authentic ribavirin resistant virus), we sub-
jected the J6/JFH1 virus to successive seven days
interval passages in naïve Huh7D cells (a highly permis-
sive clone derived from Huh7 cells[10]) that had not
previously been exposed to ribavirin as described in the
material and methods section. As shown in Figure 1, a
concentration of 125 μM ribavirin did not have a detect-
able effect on HCV replication, while 500 μMa n d1 0 0 0
μM ribavirin lead to viral extinction. Concentrations of
250 μM of ribavirin dramatically reduced virus replica-
tion which was sustained over six passages. At passage
seven, viral resurgence began and over the next two pas-
sages the level of virus reached that of the virus grown
without ribavirin. The high percentage of infected cells
observed at passage eight in cultures treated with 250
μM ribavirin suggested that the recovered virus was
resistant to ribavirin. The virus recovered from passage
s e v e ni n2 5 0μM ribavirin was grown in naïve Huh7D
cells (not treated with ribavirin) for a week and the
supernatant from this culture was harvested, titrated to
6.5 × 10
4 ffu/ml, and designated HCV-RR1.
Of note, in some experiments J6/JFH1 resurged after
several passages in 250 μM ribavirin (as in Figure 1),
while in others it resurged faster or it did not resurge at
all (not shown). The level of infected cells before virus
resurgence could explain the observed differences: in
some instances, it is possible that no infectious virus
survived after a few passages in ribavirin and therefore
the opportunity to select a resistant mutant was lost. In
addition, we observed variability in viral titers which we
don’t fully understand.
Virus recovered from ribavirin treated cells is resistant to
ribavirin
In order to test if HCV-RR1 was a truly ribavirin resis-
tant virus, J6/JFH1 and HCV-RR1 were grown in 200,
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Figure 1 Selection of HCV resistant to ribavirin. J6/JFH1 virus was serially passaged in Huh7D cells in medium containing the indicated
amount of ribavirin; at each passage intra-cellular HCV antigen was detected by immunfluorscence as described in the text. The percentage of
infected cells was calculated by dividing the estimated amount of positive cells over the total number of cells per well.
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Page 2 of 8300, or 400 μM ribavirin by serially passaging the
viruses every 5 to 7 days in naïve Huh7D cells as
described for the experiment shown in Figure 1. Virus
growth was assessed by IF (not shown) and by titration
of the supernatants from each passage, as previously
described[10](Figure 2). HCV-RR1 grew slightly better
than J6/JFH1 in 200 μM ribavirin. In 300 μM ribavirin,
HCV-RR1 grew reaching titers of 10
4 ffu/ml, while J6/
JFH1 did not survive. Neither virus survived the 400 μM
ribavirin treatment. This result indicates that viruses
recovered from the 250 μM ribavirin treated cells (Fig-
ure 1) were resistant to ribavirin. We further subjected
HCV-RR1 to ten passages in Huh7D cells treated with
250 μM ribavirin. The supernatant recovered from P10
cultures was harvested, titrated to 4.3 × 10
3 ffu/ml, and
designated HCV-RR2.
Kinetics of virus growth in 300 μM ribavirin for one week
We confirmed the ribavirin resistant phenotype of
HCV-RR1 by determining the kinetics of the growth of
J 6 / J F H 1a n dH C V - R R 2i nac o n c e n t r a t i o no fz e r oo r
300 μM ribavirin for one week as described in the mate-
rial and methods section. J6/JFH1 and HCV-RR2 grew
to similar levels in medium containing no ribavirin
(HCV-RR2 showed a faster growth kinetics in this
experiment). In medium containing 300 μM of ribavirin,
J6/JFH1 did not grow, while HCV-RR2 attained titers
similar to HCV-RR2 grown without ribavirin (Figure 3).
Virus resistant to ribavirin acquired synonymous and
non-synonymous mutations
In order to find out if ribavirin resistant viruses acquired
mutations, viral RNA from HCV-RR1 and HCV-RR2
was extracted, reverse transcribed, amplified by PCR,
and sequenced. In the coding region, HCV-RR1
acquired 26 nucleotide substitutions (relative to wild
type J6/JFH1), 11 of which predicted amino-acid
changes. These mutations were located in the core, E2,
NS2, NS5a, and NS5b proteins. The HCV-RR2 sequence
showed the same 26 substitutions found in HCV-RR1
and 12 additional nucleotide substitutions, 3 of which
resulted in amino-acid changes (one additional substitu-
tion located in NS3 and two in NS5b) (see Table 1). We
note that we found in both viruses mutation T2667C
leading to amino-acid substitution Phe to Ser in the P7
protein (F716S in the HCV polyprotein). However, we
also found this mutation in J6/JFH1 viruses that were
passed without ribavirin (unpublished results), suggest-
ing that F716S is not a ribavirin resistant determinant.
The sequence of the 5’ UTR from HCV-RR1 and HCV-
RR2 (starting at nucleotide 29) showed no mutations.
Sequence of the 3’ UTR from HCV-RR1 showed no
mutations through nucleotide 9481, while HCV-RR2
showed two mutations at the start of the polypyrimidine
[poly (U/UC)] tract: C9480T and C9481T. Although we
were able to detect the presence of the poly (U/UC)
tract (nucleotides 9478 through 9558) in both viruses,
we couldn’t accurately determine the exact number of
U/UCs. In addition, we couldn’t accurately resolve the
end of the poly (U/UC) tract, from nucleotide 9540 till
nucleotide 9558. No mutations were observed from
nucleotide 9558 till nucleotide 9640.
Discussion
In this study we obtained an HCV mutant that grows in
cultured cells in the presence of medium concentrations
of up to 300 μM ribavirin. We were able to derive this
ribavirin resistant virus by successive weekly passages of
the J6/JFH1 strain in Huh7D cells that were treated
with medium containing 250 μM ribavirin (Figure 1).
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Figure 2 HCV recovered from ribavirin treated cells is resistant to ribavirin. J6/JFH1 and HCV-RR1 were serially passaged in Huh7D cells in
medium containing the indicated concentration of ribavirin; at each passage HCV titers in the supernatants were obtained as described in the
text. Titers are expressed as the mean number of foci of each of four replicates. Error bars represent the standard deviation.
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Page 3 of 8During the first six passages, the percentage of infected
cells decreased till almost the extinction of the virus;
after passage six, virus resurged and by passage nine
more than 90% of the cells were infected. This initial
result suggested that the recovered virus was resistant to
ribavirin. We confirmed the ribavirin resistant pheno-
type of the recovered virus by infecting naïve cells and
showing that it can grow to high titers even in a con-
centration of 300 μM ribavirin (Figures 2 and 3). The
recovered virus acquired synonymous and non-synon-
ymous mutations that were distributed all along the
genome (Table 1). These mutations were maintained
after nine passages in medium without ribavirin, with
the exception of C/T1021T silent mutation in E1 (that
is a mix of C and T in HCV-RR and reverted to C by
passage nine) and C8286T that reverted to a mix of C
and T (data not shown).
The NS5b from HCV can use ribavirin triphosphate as
a nucleotide substrate, incorporating ribavirin monopho-
sphate opposite to pyrimidines (U or C) but not oppo-
site to purine (A or G) residues, leading to transition
mutations[11,12]. Out of the 38 mutations we found in
HCV-RR2, 36 were transitions and two were transver-
sions (Table 1) possibly reflecting the mutagenic effect
of ribavirin during the initial passages.
One or more of the observed mutations in HCV-RR
viruses could be responsible for the ribavirin resistant
phenotype. The above mentioned studies and studies
showing that ribavirin increases the mutation rate of
HCV in cultured cells [13-16] and in vivo [15,17]
(although others did not observe an increase in muta-
tion frequency[18,19]) point to NS5b as a possible
genetic determinant of resistance to ribavirin. In our
newly described HCV-RR viruses we found mutation
Ser to Asn at amino-acid 15 of NS5b. According to
crystallographic studies amino-acid 15 is located in the
finger domain of NS5b[20-22]. Interestingly, this region
is structurally related to the region where a single point
mutation (G64S in the RNA polymerase) confers resis-
tance to the catastrophic error[23] caused by ribavirin in
poliovirus[24-26].
We do not know at this time the in vivo relevance of
our results. It can be argued that in chronically infected
patients subjected to ribavirin and interferon combina-
tion therapy, the plasma ribavirin concentration, esti-
mated to be around 10 μM[27-29], is lower than the
concentrations we needed to suppress HCV replication
in our system. However, we don’t know the concentra-
tion of ribavirin in hepatocytes, nor do we know the
intracellular concentration of ribavirin in Huh7D cells.
In one clinical report[30], while plasma ribavirin con-
centrations were of 8.8 μM, erythrocyte ribavirin con-
centrations were of 1389 μM, more than 150 times
higher. This observation suggests that intracellular riba-
virin could also be higher in cells other than erythro-
cytes, i.e. hepatocytes, compared to plasma.
Conclusion
Ribavirin has proven to be effective for the treatment of
HCV chronically infected patients when combined with
interferon. Given the side effects associated with intrave-
nous injections of interferon, an interferon-free regimen
for the treatment of HCV infections is highly desirable.
The study of HCV resistance to ribavirin could be spe-
cially important for an interferon-free era. In this report,
we show that it is possible to select a ribavirin resistant
Limit of detection
0 PM ribavirin 300 PM ribavirin
0.1
1
10
100
1000
10000
100000
1000000
012345678
days post infection
t
i
t
e
r
s
 
(
f
f
u
/
m
l
)
WT
HCV-RR2
0.1
1
10
100
1000
10000
100000
1000000
012345678
days post infection 
t
i
t
e
r
s
 
(
f
f
u
/
m
l
)
WT
HCV-RR2
Figure 3 Growth of HCV in 300 μM ribavirin for one week. Huh7D cells were mock infected or infected with wild type J6/JFH1 or HCV-RR2
at a m.o.i. of 0.01. After 6 hours, cells were washed with growth medium three times and passed by tripsinization to 12 well plates containing a
final concentration of zero or 300 μM ribavirin. Cells were collected at the indicated time points and frozen at -70°C. Virus was tittered as
described in the text. Titers are expressed as the mean number of foci of each of four replicates. Error bars represent the standard deviation.
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Page 4 of 8Table 1 Mutations observed in HCV resistant to ribavirin
Nucleotide
position*
Nucleotide in
J6/JFH1
Nucleotide in
HCV-RR1
Nucleotide in
HCV-RR2
Protein Amino-acid
position*
&
Amino-acid in
J6/JFH1
Amino-acid in
HCV-RR1
Amino-acid in
HCV-RR2
367 A C C core 9 R S S
376 A G G
572 A G G 78 K E E
581 T C C 81 Y H H
773 G A A 145 G S S
901 C T T
1021
# CT T E 1
1691 G A A E2 451 G R R
1855 T C C
1996 C C T
2492 G A A 718 V I I
2667
^ T C C P7 776 F S S
2803 G G A NS2
3050 T C C 904 Y H H
3369 T G G 1010 L R R
3520 C C T NS3
3691 C T T
4937 G G A 1533 D D N
5143 C T T
5473 G G A NS4a
5686 G G A NS4b
5704 C C T
5753 T C C
6583 C T T NS5a
7216 C T T
7320 C T T 2327 P L L
7441 G A A
7573 T C C
7652 A G G 2438 T A A
7710 G A A NS5b 2457 S N N
7996 C T T
8065 A G G
8188 C C T
8286 C C T 2649 A A V
8359 A G G
8911 T T C
8971 C C T
9018 T T C 2893 V V A
9082 T C C
* nomenclature is according to the JFH1 sequence, accession number AB047639.
&Only amino-acids where a substitution in HCV-RR viruses was found are indicated.
# Position 1021 is a mix of C and T in HCV-RR1 and HCV-RR2.
^ T2667C was also found in J6/JFH1 viruses that were passed without ribavirin (unpublished results).
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Page 5 of 8mutant of HCV in vitro that can replicate to similar
levels to virus grown without ribavirin. Analysis of the
mutations responsible for the ribavirin resistance pheno-
type, currently underway, may aid in understanding the
mechanism of action of ribavirin.
Methods
Cells
Huh7D cells, a highly permissive clone derived from
Huh7 cells
8 w e r eg r o w ni nD M E M( G i b c o )s u p p l e m e n -
ted with 10% bovine calf serum (Atlanta Biologicals), L-
glutamine (Gibco), penicillin, and streptomycin (Gibco)..
Viruses
To obtain the J6/JFH1, plasmid pFL- J6/JFH1[8] (a plasmid
coding for full length J6/JFH1 virus, kindly provided by Dr
Charles Rice) or the corresponding recombinant plasmids
were cut with restriction enzyme Xba1 and transcribed
with T7 RNA polymerase following the manufacturer
instructions (T7 Megascript AMBION). In vitro transcribed
HCV RNA was mixed with lipofectamine 2000 (Invitrogen)
in Optimem (Gibco) and transfected into Huh7D cells.
HCV replication was confirmed by immunfluorscence as
described below. Virus from transfected cells was amplified
by inoculating the supernatants from transfected cells into
naïve Huh7D cells. Virus stocks were made from the super-
natants of infected cells and titered as described below.
Antibodies
Monoclonal antibody 6G7 directed to the HCV core
protein was kindly provided by Henry H. Hsu and Harry
B. Greenberg (Stanford University, Palo Alto Veterans
Administration Medical Center, Palo Alto, CA)[31].
Infection of Huh7D cells with wild type or ribavirin
resistant J6/JFH1 viruses and treatment with ribavirin
Huh7D cells grown in 48-well plates were mock infected
or infected with the indicated virus at a moi of 0.01. At
5t o7h o u r sp o s ti n f e c t i o n ,m e d i u mw a sr e p l a c e dw i t h
500 μl of medium containing the indicated amount of
ribavirin. At 6 or 7 days post infection, 200 μlo ft h e
supernatants were used to inoculate naïve Huh7D cells
that were seeded the day before, and at 5 to 7 hours
post infection medium was replaced with 500 μl of med-
ium containing the corresponding amount of ribavirin.
The rest of the supernatants were stored at -70°C. This
procedure was repeated for the indicated number of
passages. HCV antigen was detected in the remaining
monolayers by immunfluorscence (IF) and HCV titers
were obtained from the supernatants as described below.
Growth of HCV in 300 μM ribavirin for one week
Huh7D cells grown in 6-well plates were mock infected
or infected with J6/JFH1 or HCV-RR2 at a moi of 0.01.
At 6 hours post infection, cells were washed three times
with medium and split into 12-well plates containing a
final concentration of zero or 300 μM of ribavirin. At 0,
1, 3, 5, and 7 dpi the 12-well plates were frozen at -70°
C. Total virus from each time point was recovered by
freezing and thawing the cells 3 times and titered.
Titration of viruses
To obtain virus titers, monolayers of Huh7D cells grown
in 96 well plates were infected with 100 μl of 10-fold
serial dilutions of the corresponding virus (in quadrupli-
cates). At three days post infection, viral antigen was
detected by IF as described below. Foci were counted
and titers were expressed as the mean number of foci of
each of the four replicates +/- the standard deviation.
Detection of HCV antigen by immunfluorscence (IF)
Infected cells were fixed with methanol, washed with
1×PBS, blocked with a solution containing 1% BSA and
0.2% non-fat milk in 1×PBS, washed with 1×PBS, treated
with a 1:500 dilution of monoclonal antibody 6G7 in
0.05% tween 20 in 1×PBS, washed with 1×PBS, stained
with FITC-conjugated goat anti-mouse antibody (KPL),
washed with 1×PBS, and observed in the microscope
under UV light. The percentage of positive cells was
determined by dividing the estimated amount of positive
cells over the total number of cells per well.
Sequencing of ribavirin resistant viruses
Viral RNA was extracted from virus stocks using Trizol
reagent as recommended by the manufacturer (Invitro-
gen). cDNA was synthesized using SuperScript III
reverse transcriptase and random primers (Invitrogen).
PCR amplification of the HCV genome was performed
using the Expand High Fidelity PCR system (Roche) as
recommended by the manufacturer and the following
sets of primers: 2a10+ and 2a1260-, 2a1101+ and
2a2690- (5’- CCTTGATGTACCAAGCAGCC-3’),
2a2431+ (5’-CCAAAACATCGTGGACGTAC-3’)a n d
2a3980- (5’-AAGTGGGAGACCTTGTAACA-3’),
2a3721+ (5’-CAAGTGTGGAGCCGTCGACC-3’)a n d
2a6320- (5’-CTGTCAAGATGGTGCAAACC, 2a6181+
(5’-TGTGACCCAACTACTTGGCT-3’) and negNS5b15-
mut, 2a6781+ (5’-TGAGGTCTCGTTCTGCGTTG-3’)
and 2a8760- (5’-GATGTTATTAGCTCCAGGTC-3’),
2a8521+ (5’-AACCACTAGCATGGGTAACA-3’)a n d
2a9480- (5’- GAACAGTTAGCTATGGAGTG-3’),
2a9001+ (5’- TGAGATGTATGGATCAGTAT -3’)o r
2a9040+ (5’- CTTCCAGCCATAATTGAGAG -3’)a n d
2a9660- (5’-CCAGTTACGGCACTCTCTGC -3’)o r
2a9678- (5’-ACATGATCTGCAGAGAGACC-3’). PCR
products were run in agarose gels and purified using
gene-elute agarose gel columns (Sigma) or the QIAquick
PCR purification Kit (Qiagen) and sequenced using the
Feigelstock et al. Virology Journal 2011, 8:402
http://www.virologyj.com/content/8/1/402
Page 6 of 8BigDye terminator v3.1 cycle-sequencing kit (Applied
Biosystems) and the 3130xl Genetic analyzer (Applied
Biosystems). In addition to the oligos used for PCR, we
used the following oligos for sequencing: 2a4280- (5’-
AGGCGCCGCTAGCGCAGCCC-3’), 2a4431+ (5’-CCG
ATATAGAAGAGGTAGGC-3’), 2a5051+ (5’-CACATA
GACGCCCACTTCCT-3’), 2a7860- (5’-TCATAATGG
GCGTCGAGCAC-3’) and 2a9561+ (5’-CTTATTC
TACTTTCTTTCTT-3’).
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